RICHMOND, Va.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology.

Titled, “A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination,” the publication describes a model developed with Dr. Lisette de Pillis, a professor of life sciences and mathematics at Harvey Mudd College.

NAb inhibit viral binding to the human cell receptor thereby reducing its ability to infect the cell. Evaluating NAb levels and their durability over time is important in understanding unique immune responses and the likelihood of an individual having protective immunity against infection, the researchers state. AditxtScore’s™ model uses a novel flow-cytometry-based immune monitoring tool to determine levels of NAb following immunization.

The publication details a promising mathematical model that can serve as a foundation for predicting the decay rate of NAb over time. The model can assess variations in immune response against viral infection and vaccination to provide the opportunity for a more personalized approach to immunization protocols.

Knowing an individual’s NAb level and how one’s personal immune system responds to infection provides a valuable tool for health care providers and patients as they chart an individual’s current and future health care needs.

Researchers concluded there are several potential applications for the AditxtScore™ model, including:

• Determining immune response on a case-by-case basis to identify vulnerable populations;
• Aiding vaccine development by reducing clinical trial timelines and identifying vaccines that lead to a more robust immune response; and
• More accurately assessing the timing of boosters on a personalized level.

To read the AditxtScore™ research paper published in the Journal of Theoretical Biology, visit: https://www.sciencedirect.com/science/article/pii/S0022519322002715

About Aditxt, Inc.

Aditxt is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

For more information, please visit: www.Aditxt.com and www.AditxtScore.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005475/en/